. Author manuscript; available in PMC: 2012 May 22.

Published in final edited form as: Curr Opin Pediatr. 2011 Feb;23(1):98–104. doi: 10.1097/MOP.0b013e328341d1f5

Table 2a.

IgG Sero-responses for the 6 Additional PCV13 Serotypes ^[35]

	Proportion over 0.35 ug/ml after dose 3	GMC^* After dose 3
Serotype	%	GMC (95% CI)
1	95.6	2.03 (1.78, 2.32)
3	63.5	0.49 (0.43, 0.55)
5	89.7	1.33 (1.18, 1.50)
6A	96.0	2.19 (1.93, 2.48)
7F	98.4	2.57 (2.28, 2.89)
19A	98.4	2.07 (1.87, 2.30)

Geometric mean concentration 1 month after 3^rd dose in Primary series (2, 4 and 6 months of age)

^{[Data from 35}} FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee. November 18, 2009.